Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12805446 | 1.00 | TRPM8 (0.58) | TRPM8EPHX1TRPA1TRPV1CYP19A1 | |
| SCHEMBL15857921 | 1.00 | TRPM8 (0.58) | TRPM8EPHX1TRPA1TRPV1CYP19A1 | |
| SCHEMBL15054395 | 0.89 | TRPM8 (0.55) | TRPM8EPHX1TRPA1TRPV1CYP19A1 | |
| SCHEMBL24540799 | 0.89 | TRPM8 (0.55) | TRPM8EPHX1TRPA1TRPV1CYP19A1 | |
| SCHEMBL1603431 | 0.89 | TRPM8 (0.55) | TRPM8EPHX1TRPA1TRPV1CYP19A1 | |
| SCHEMBL14580757 | 0.88 | TRPM8 (0.68) | TRPM8EPHX1TRPA1CYP19A1EPHX2 | |
| SCHEMBL20930061 | 0.88 | TRPM8 (0.68) | TRPM8EPHX1TRPA1CYP19A1EPHX2 | |
| SCHEMBL22460370 | 0.88 | TRPM8 (0.68) | TRPM8EPHX1TRPA1CYP19A1EPHX2 | |
| SCHEMBL14565725 | 0.88 | TRPM8 (0.68) | TRPM8EPHX1TRPA1CYP19A1EPHX2 | |
| SCHEMBL14565723 | 0.88 | TRPM8 (0.68) | TRPM8EPHX1TRPA1CYP19A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656144-B2 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-7893072-B2 | Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893072-B2 | Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-4136163-A | P-MENTHANE CARBOXAMIDES HAVING A PHYSIOLOGICAL COOLING EFFECT | WILKINSON SWORD LIMITED (GB) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | TSG101, TP53, BAX | TRPM8 28/4885EPHX1 1033/4885TRPA1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.